Executive at a global CDMO
- Key customer purchasing criteria for bioprocessing equipment across upstream and downstream bioprocessing workflows
- Incumbent benchmarking vs key purchasing criteria – Sartorius (ETR: SRT) vs Danaher (NYSE: DHR), Thermo Fisher (NYSE: TMO), Repligen (NASDAQ: RGEN) and Merck Millipore (ETR: MRK)
- Evolving SUT (single-use technology) requirements and vendor positioning across modalities and end markets including mAbs (monoclonal antibodies), C> (cell and gene therapy) and ATMP (advanced therapeutic medicinal products)
- Mid-to-long-term price and volume outlook for SUT bioprocessing equipment, touching on dynamics with CDMOs (contract development and manufacturing organisations)
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.